MYOF and breast cancer: Collectively, our results demonstrated that WJ460 can serve as a first lead compound for the development of MYOF-targeted therapeutic agents and targeting MYOF by WJ460 may be a promising therapeutic strategy in MYOF-driven breast cancer.